AKT1 and triple-negative breast carcinoma: In contrast, AKT inhibitors in combination with paclitaxel have been shown to be more active in patients with triple-negative breast cancers harboring a PIK3CA/PTEN/AKT1 pathway alteration.7,10 Similarly, PI3K inhibitors have demonstrated activity in patients with PIK3CA mutations.22,23